siRNA for AGT gene expression inhibition in hypertension treatment
Summary
The USPTO has published a new patent application (US20260085317A1) detailing modified oligonucleotide sequences designed as siRNAs to inhibit angiotensinogen (AGT) gene expression. The application suggests these siRNAs may be used in the development of treatments for hypertension and related diseases.
What changed
This document is a patent application (US20260085317A1) filed with the USPTO, disclosing novel siRNA sequences designed to target and inhibit the angiotensinogen (AGT) gene. The application details specific modifications to these oligonucleotide sequences and presents experimental data from cell and animal studies demonstrating their efficacy in significantly inhibiting AGT gene expression. The inventors propose that these siRNAs have potential applications in developing new medicaments for treating hypertension and associated conditions.
As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future developments in pharmaceutical treatments for hypertension. Companies involved in biotechnology, pharmaceutical research, and the development of oligonucleotide-based therapies should monitor this and related patent filings. The publication of this application may impact intellectual property landscapes and future research and development strategies in the cardiovascular and genetic therapy sectors.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SIRNA FOR TARGETED INHIBITION OF AGT GENE EXPRESSION AND USE THEREOF IN TREATING HYPERTENSION
Application US20260085317A1 Kind: A1 Mar 26, 2026
Inventors
Gengshen Song, Zeao Huang, Shuo Yang, Guangshen Ji, Zhikang Tian, Yucheng Wu, Zhongcai Gao, Wei Zhang, Man Zhang
Abstract
The present disclosure provides a modified oligonucleotide sequence and use thereof. A series of siRNAs were designed based on the angiotensinogen (AGT) messenger ribonucleic acid (mRNA) sequence, which were alternately modified or modified using a specific set of modification templates. The results from cell and animal experiments demonstrated that some oligonucleotide sequences with alternating modifications and specific template modifications can significantly inhibit AGT gene expression and may be used for the development of medicaments for treating hypertension and other related diseases.
CPC Classifications
C12N 15/113 A61K 31/7115 A61K 31/712 A61K 31/7125 A61K 31/713 A61P 9/12 C12N 2310/11 C12N 2310/14 C12N 2310/3125 C12N 2310/315 C12N 2310/321 C12N 2310/322 C12N 2310/335 C12N 2310/336 C12N 2310/351
Filing Date
2025-09-26
Application No.
19341325
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.